Newsbenzinga
Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy
· Published
Article summary
Surrozen submitted an IND application to the FDA for SZN-8141 to treat diabetic macular edema, with trial data expected in late 2027.
An excerpt from the original article.
Comments —
Loading comments…